Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2013 1
2014 3
2015 2
2016 2
2017 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
Crizotinib targets in glioblastoma stem cells.
Junca A, Villalva C, Tachon G, Rivet P, Cortes U, Guilloteau K, Balbous A, Godet J, Wager M, Karayan-Tapon L. Junca A, et al. Among authors: guilloteau k. Cancer Med. 2017 Nov;6(11):2625-2634. doi: 10.1002/cam4.1167. Epub 2017 Sep 27. Cancer Med. 2017. PMID: 28960893 Free PMC article.
A radiosensitizing effect of RAD51 inhibition in glioblastoma stem-like cells.
Balbous A, Cortes U, Guilloteau K, Rivet P, Pinel B, Duchesne M, Godet J, Boissonnade O, Wager M, Bensadoun RJ, Chomel JC, Karayan-Tapon L. Balbous A, et al. Among authors: guilloteau k. BMC Cancer. 2016 Aug 5;16:604. doi: 10.1186/s12885-016-2647-9. BMC Cancer. 2016. PMID: 27495836 Free PMC article.
IL22/IL-22R pathway induces cell survival in human glioblastoma cells.
Akil H, Abbaci A, Lalloué F, Bessette B, Costes LM, Domballe L, Charreau S, Guilloteau K, Karayan-Tapon L, Bernard FX, Morel F, Jauberteau MO, Lecron JC. Akil H, et al. Among authors: guilloteau k. PLoS One. 2015 Mar 20;10(3):e0119872. doi: 10.1371/journal.pone.0119872. eCollection 2015. PLoS One. 2015. PMID: 25793261 Free PMC article.
A mesenchymal glioma stem cell profile is related to clinical outcome.
Balbous A, Cortes U, Guilloteau K, Villalva C, Flamant S, Gaillard A, Milin S, Wager M, Sorel N, Guilhot J, Bennaceur-Griscelli A, Turhan A, Chomel JC, Karayan-Tapon L. Balbous A, et al. Among authors: guilloteau k. Oncogenesis. 2014 Mar 17;3(3):e91. doi: 10.1038/oncsis.2014.5. Oncogenesis. 2014. PMID: 24637491 Free PMC article.
Selective release of a cyclopamine glucuronide prodrug toward stem-like cancer cell inhibition in glioblastoma.
Balbous A, Renoux B, Cortes U, Milin S, Guilloteau K, Legigan T, Rivet P, Boissonnade O, Martin S, Tripiana C, Wager M, Bensadoun RJ, Papot S, Karayan-Tapon L. Balbous A, et al. Among authors: guilloteau k. Mol Cancer Ther. 2014 Sep;13(9):2159-69. doi: 10.1158/1535-7163.MCT-13-1038. Epub 2014 Jul 22. Mol Cancer Ther. 2014. PMID: 25053823 Free article.
EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients.
Villalva C, Duranton-Tanneur V, Guilloteau K, Burel-Vandenbos F, Wager M, Doyen J, Levillain PM, Fontaine D, Blons H, Pedeutour F, Karayan-Tapon L. Villalva C, et al. Among authors: guilloteau k. Cancer Med. 2013 Jun;2(3):296-304. doi: 10.1002/cam4.82. Epub 2013 Apr 23. Cancer Med. 2013. PMID: 23930206 Free PMC article.